New approaches to therapies for the treatment or cure of disease continue to struggle with an unmanageable flood of genetic information generated in hundreds of laboratories around the world. Shaping the mass of information into forms that can lead to the design and testing of actual therapies - and integrating the genetic information to understand how genes act and interact to cause common diseases - may be the greatest challenges facing pharmaceutical researchers.

An Alameda, Calif., genomics company, gene/Networks, hopes to meet those challenges through the accelerated identification of multiple-gene pathways - or gene networks - as opposed to individual gene discoveries.